Skip to main content

Table 2 CTV Dmax, HI, CI, V95 and anorectum/bladder V4000cGy, V6500cGy, and V8000cGy dose statistics for all cohorts analyzed

From: Assessment of IMPT versus VMAT plans using different uncertainty scenarios for prostate cancer

 

Nominal Plans

Uncertainty Plans

Cohort

VMATorig

IMPTRO3

IMPTRO5

VMAT3mm

IMPT3%/3 mm

VMAT5mm

IMPT3%/5 mm

CTV Dmax

Mean

110.0 ± 1.7

108.0 ± 1.6

109.7 ± 1.8

110.0 ± 1.7

106.8 ± 1.1

110.0 ± 1.8

108.7 ± 1.9

Range

107.4–113.8

104.5–110.6

106.8–113.8

106.7–114.5

104.2–110.0

106.7–114.4

104.0–114.6

Failure rate of uncertainty plans (%)

 

0.0

 0.0

 0.0

 0.0

CTV homogeneity index (HI)

Mean

0.05 ± 0.01

0.03 ± 0.01

0.05 ± 0.01

0.05 ± 0.01

0.06 ± 0.02

0.07 ± 0.03

0.09 ± 0.04

Range

0.03–0.08

0.02–0.04

0.03–0.06

0.03–0.10

0.01–0.10

0.04–0.25

0.04–0.26

CTV conformity index (CI)

Mean

1.8 ± 0.1

1.5 ± 0.1

1.7 ± 0.2

1.8 ± 0.1

1.2 ± 0.1

1.8 ± 0.1

1.5 ± 0.2

Range

1.6–2.0

1.2–1.7

1.4–2.0

1.6–2.0

0.8–1.6

1.6–2.0

1.0–2.0

CTV V95%

Mean

99.9 ± 0.1

100.0 ± 0.0

100.0 ± 0.0

99.9 ± 0.2

99.6 ± 0.4

99.7 ± 0.7

98.8 ± 1.2

Range

99.7–100.0

100.0

100.0

98.3–100.0

97.5–100.0

94.5–100

95.4–100

Failure rate of uncertainty plans (%)

0.0

 0.0

 0.0

 0.0

Anorectum (V4000cGy)

Mean

20.4 ± 6.3

13.8 ± 4.4

15.3 ± 5.3

20.7 ± 8.2

14.0 ± 6.2

21.2 ± 10.2

15.8 ± 9.0

Range

10.4–32.7

6.6–22.8

7.7–27.9

5.00–45.7

3.0–32.0

2.1–53.7

1.7–42.5

Failure rate of uncertainty plans (%)

4.6

 0.0

 8.7

 3.1

Anorectum (V6500cGy)

Mean

7.0 ± 2.9

5.1 ± 2.5

6.4 ± 3.5

7.4 ± 4.9

5.5 ± 4.0

8.1 ± 6.5

7.4 ± 6.4

Range

2.8–14.4

1.8–9.3

2.4–15.3

0.1–22.8

0.1–17.0

0.0–28.9

0.0–27.1

Failure rate of uncertainty plans (%)

5.1

 0.3

 10.9

 8.6

Anorectum (V8000cGy)

Mean

0.9 ± 1.1

0.5 ± 0.8

1.1 ± 1.8

1.4 ± 2.3

0.8 ± 1.5

1.8 ± 3.0

1.9 ± 3.4

Range

0.0–3.5

0.0–2.6

0.0–7.7

0.0–12.3

0.0–7.1

0.0–12.4

0.0–17.7

Failure rate of uncertainty plans (%)

0.6

 0

 3.0

 5.8

Bladder (V4000cGy)

Mean

21.9 ± 11.4

13.7 ± 7.3

15.3 ± 7.7

21.9 ± 11.9

13.5 ± 7.8

21.9 ± 12.8

15.1 ± 9.3

Range

3.4–44.5

1.8–31.5

2.2–31.1

2.3–53.4

1.0–42.0

1.7–60.9

0.9–46.0

Failure rate of uncertainty plans (%)

1.1

 0.0

 1.7

 0.0

Bladder (V6500cGy)

Mean

8.5 ± 4.7

6.0 ± 3.5

7.4 ± 3.9

8.6 ± 5.4

5.9 ± 4.4

8.7 ± 6.5

7.6 ± 5.9

Range

1.2–19.7

0.6–14.3

0.8–15.2

0.6–28.4

0.2–25.1

0.3–34.7

0.1–30.7

Failure rate of uncertainty plans (%)

1.1

 0.3

 2.3

 0.9

Bladder (V8000cGy)

Mean

2.5 ± 2.3

0.6 ± 0.9

1.3 ± 1.3

2.7 ± 2.9

0.6 ± 1.2

2.9 ± 3.6

1.4 ± 2.1

Range

0.0–8.3

0.0–3.2

0.0–4.3

0.0–15.6

0.0–9.39

0.0–20.9

0.0–11.7

Failure rate of uncertainty plans (%)

2.4

0.0 

 4.8

 0.6

  1. Left and right sided columns give mean, standard deviations, minimum, and maximum doses statistics for all nominal and uncertainty cohorts, respectively. For each uncertainty cohort, the percentage of dose distributions that did not reach each clinical dose objective is additionally given. Bold and Italicized values indicate statistically significant differences between IMPT and VMAT cohorts with equivalent and non-equivalent geometric uncertainties, respectively. Underlined values indicate that the within similar modalities, one cohort significantly outperformed the other with different geometric uncertainties